Cancer Cachexia Pipeline: Emerging Therapies Set to Transform the Cancer Cachexia Treatment Landscape | DelveInsight

The treatment landscape for Cancer Cachexia, a multifactorial syndrome characterized by progressive weight loss, muscle wasting, and fatigue in cancer patients, is undergoing significant evolution, driven by an expanding pipeline of novel therapeutics. Leading pharmaceutical and biotech companies are focusing on addressing the underlying mechanisms of cachexia, including inflammation, muscle degradation, and metabolic disturbances. Key players like Actimed Therapeutics Ltd, Pfizer, AVEO Pharmaceuticals, and NGM Biopharmaceuticals are leading the charge with innovative therapies targeting cytokine pathways, anabolic agents, and metabolic reprogramming.

DelveInsight's "Cancer Cachexia - Pipeline Insight, 2025" provides an in-depth analysis of the current clinical development landscape, highlighting investigational therapies at various stages, ranging from early-stage preclinical development to advanced Phase III trials. The report identifies key drug candidates, their mechanisms of action, clinical development status, and anticipated market entry dates.

This pipeline assessment offers a comprehensive 360° view of cancer cachexia therapeutic development trends, categorizing therapies by drug types, administration routes, and clinical phases. It also focuses on unmet needs, emerging market disruptors, and regulatory designations, such as fast track and orphan drug status, that are poised to reshape the treatment standards for cancer cachexia in the near future. With promising therapies in the pipeline, these advancements hold the potential to significantly improve the quality of life and survival rates for cancer patients suffering from cachexia.

Interested in learning more about the current treatment landscape and the key drivers shaping the cancer cachexia pipeline? Click here: https://www.delveinsight.com/report-store/cancer-cachexia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Cancer Cachexia Pipeline Report
• DelveInsight's cancer cachexia pipeline analysis depicts a strong space with 12+ active players working to develop 15+ pipeline drugs for cancer cachexia treatment.
• The leading cancer cachexia companies include Actimed Therapeutics Ltd, Pfizer, AVEO Pharmaceuticals, NGM Biopharmaceuticals, Endevica Bio, CSPC Pharmaceutical Group Limited, Caelus Health, and others are evaluating their lead assets to improve the cancer cachexia treatment landscape.
• Key cancer cachexia pipeline therapies in various stages of development include ACM-001.1, Ponsegromab, AV-380, NGM120, TCMCB07, JMT203, CH 0701, and others.
• In March 2025, Dr. Andrew Hendifar announced a study to evaluate the impact of adding Pancreaze (pancrelipase) delayed-release capsules-84,000-lipase units for main meals and 42,000-lipase units for snacks-to the standard of care in patients with exocrine pancreatic insufficiency caused by pancreatic adenocarcinoma. The study will assess weight stability, functional changes, and quality of life.
• In September 2024, researchers reported in the New England Journal of Medicine the results of a Phase II clinical trial involving 187 cancer patients with cachexia due to lung, pancreatic, or colorectal cancer. The study found a drug that safely and effectively alleviated weight loss and muscle wasting associated with the condition.

Request a sample and discover the recent breakthroughs happening in the cancer cachexia pipeline landscape @ https://www.delveinsight.com/report-store/cancer-cachexia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Cancer Cachexia Overview
Cancer cachexia is a debilitating syndrome that severely impacts patients' quality of life and is linked to poor chemotherapy responses and reduced survival. It is prevalent in the majority of terminal cancer patients, responsible for the death of approximately 22% of cancer patients. Cachexia causes significant loss of skeletal muscle and body fat and is often a complication of various cancers, particularly pancreatic and gastric cancers, where it affects up to 87% of patients. It also occurs in breast cancer, sarcoma, leukemia, and Hodgkin lymphoma at a rate of around 40%.

The condition is characterized by systemic inflammation, negative energy balance, and involuntary loss of lean body mass, leading to weight loss and disruptions in metabolic balance. Early recognition of these symptoms, including weight loss exceeding 5% within six months, decreased food intake, and reduced muscle strength, is essential for timely intervention and management.

Diagnosis is based on clinical signs, laboratory tests indicating anemia or elevated inflammatory markers, and imaging studies to assess tumor burden. Ruling out other causes of weight loss and muscle wasting is crucial. Once diagnosed, treatment requires a multidisciplinary approach, including symptom management, nutritional support, physical activity, and addressing the underlying cancer, to improve patients' quality of life and potentially enhance treatment outcomes.

Find out more about cancer cachexia medication @ https://www.delveinsight.com/report-store/cancer-cachexia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Cancer Cachexia Treatment Analysis: Drug Profile
ACM-001.1: Actimed Therapeutics Ltd
S-pindolol (ACM-001) is a multifunctional anabolic/catabolic transforming agent designed to address cancer cachexia through three primary pharmacological mechanisms: (1) β-1 receptor antagonism to reduce catabolism, (2) partial β2 receptor agonism to promote muscle growth and anabolism, and (3) central 5-HT1a antagonism to alleviate appetite loss and fatigue. Currently, ACM-001 is undergoing Phase II/III clinical trials for the treatment of cancer cachexia.

Ponsegromab: Pfizer
Ponsegromab is a monoclonal antibody targeting human growth differentiation factor 15 (GDF15), a key cytokine involved in cachexia. By binding to GDF15, ponsegromab prevents its interaction with the GFRAL receptor, blocking GDF15/GFRAL-mediated signaling, which plays a critical role in appetite loss and weight reduction. The drug is currently in Phase II clinical trials for cancer cachexia.

AV-380: AVEO Pharmaceuticals, Inc.
AV-380 is a novel humanized inhibitory antibody targeting GDF15, a cytokine associated with cachexia in cancer patients. Elevated GDF15 levels contribute to cachexia symptoms such as severe weight loss, muscle wasting, anemia, and inflammation. AV-380 works by inhibiting GDF15, potentially mitigating these cachexia-related symptoms. The drug is in Phase I clinical trials for the treatment of cancer cachexia.

Learn more about the novel and emerging cancer cachexia pipeline therapies @ https://www.delveinsight.com/report-store/cancer-cachexia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Cancer Cachexia Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

By Molecule Type
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Scope of the Cancer Cachexia Pipeline Report
• Coverage: Global
• Key Cancer Cachexia Companies: Actimed Therapeutics Ltd, Pfizer, AVEO Pharmaceuticals, NGM Biopharmaceuticals, Endevica Bio, CSPC Pharmaceutical Group Limited, Caelus Health, and others.
• Key Cancer Cachexia Pipeline Therapies: ACM-001.1, Ponsegromab, AV-380, NGM120, TCMCB07, JMT203, CH 0701, and others.

Dive deep into rich insights for drugs used for cancer cachexia treatment; visit @ https://www.delveinsight.com/report-store/cancer-cachexia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Cancer Cachexia Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Cancer Cachexia Pipeline Therapeutics
6. Cancer Cachexia Pipeline: Late-Stage Products (Phase III)
7. Cancer Cachexia Pipeline: Mid-Stage Products (Phase II)
8. Cancer Cachexia Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.